Abstract: A method of inducing uterine contraction which comprises administering, to a subject in need of such contraction, a uterine-contractionally effective amount of a prostanoic acid derivative selected from the group consisting ofa) 15-ketoprostaglandin E compounds, andb) 15-ketoprostaglandin F compounds with the proviso that when the only one group, which is unsubstituted n-pentyl group, is attached to the carbon atom at the 15-position of the prostanoic acid nucleus and the bond between the carbon atoms at 5- and 6-positions is a double bond, then the bond between the carbon atoms at 13- and 14-positions is a single bond.

Abstract: This invention provides a hypersphyxia-causing composition containing 15-keto-PGEs esters separated from any substantial activity such as decrease of blood pressure.The present invention provides a hypersphyxia-causing composition effective to recovery of blood pressure, and heart rate in e.g. hemmorrhage shock, or hyperventilation, which comprises 15-keto PGEs esters.

Abstract: The novel 13,14-dihydro-15-keto prostaglandins E of the invention have remarkable preventive effects against ulcers. Further, the novel 13,14-dihydro-15-keto-prostaglandins E of the invention have an advantage that they have none of side effects which prostaglandin E intrinsically has, or can remarakably reduce such effects of the prostaglandin E. Therefore, the novel 13,14-dihydro-15-keto prostaglandins E of the invention are effective for animal and human use for treatment and prevention of ulcers, such as duodenal ulcer and gastric ulcer.

Abstract: The present invention provides novel prostaglandins D, that is, 13,14-dihydro-15-keto-PGDs, which have an excellent sedative and sleep-inducing activity, and so they are useful for tranquilizer and/or soporifics.

Abstract: A method of treatment for improving encephalic function which comprises administering, to a subject in need of such treatment, a 15-keto-prostaglandin compound in an amount effective for improvement of encephalic function.

Abstract: The present invention provides new compounds, 13,14-dihydro-15-keto-PGFs, and vassopressors containing them, which raise blood pressure without substantial ephemeral depression of blood pressure, trachea or enteron contraction effect inherent in usual PGFs.

Abstract: The present invention relates to a new prostagrandine I analogous compounds represented by the following formula (I) and (II). ##STR1## wherein R.sub.1 is a hydrogen atom or alkyl group, at least one of R.sub.2 and/or R.sub.2 ' are a halogen atom, an alkyl group, a group containing an aromatic group, a hydroxyl group or an alkoxy group providing that the R.sub.2 and R.sub.2 ' are not simultaneously hydrogen atoms or salt thereof, which compound is expected as hypotensives.

Abstract: The present invention provides novel prostaglandins D, that is, 13,14-dihydro-15-keto-PGDs, which have an excellent sedative and sleep-inducing activity, and so they are useful for tranquilizer and/or soporifics.

Abstract: This invention provides a fervescence composition containing 15-keto-PHEs separated from any substantial activity such as decrease of blood pressure.

Abstract: The present invention relates to ocular hypotensive agents which contains 13,14-dihydro-15-keto-prostagrandins, which shows no transient ocular hypertensive response that PGs usually show.

Abstract: The present invention provides new compound, 10-substituted-5,9-dioxatricyclo[6.4.0.0.sup.2,6 ]dodecane-4-one, which is very useful as an intermediate for prostaglandin synthesis.

Abstract: The present invention provides new compound, 10-substituted-5,9-dioxatricyclo[6.4.0.0.sup.2,6 ]dodecane-4-one, which is very useful as an intermediate for prostaglandin synthesis.